Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Blood

Volumn 118, Issue 24, 2011, Pages 6292-6298

  Böll, Boris ^a,b   Bredenfeld, Henning ^b   Görgen, Helen ^b   Halbsguth, Teresa ^a,b   Eich, Hans T ^a,b   Soekler, Martin ^c   Markova, Jana ^d   Keller, Ulrich ^e   Graeven, Ullrich ^f   Kremers, Stephan ^g   Geissler, Michael ^h   Trenn, Guido ⁱ   Fuchs, Michael ^a,b   Von Tresckow, Bastian ^a,b   Eichenauer, Dennis A ^a,b   Borchmann, Peter ^a,b   Engert, Andreas ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Study Group   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Klinikum Maria Hilf Mönchengladbach   (Germany)

^g Caritas Hospital Lebach   (Germany)

^h Hospital Esslingen   (Germany)

ⁱ Knappschaftskrankenhaus Bottrop   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE; PREDNISONE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 83455220148     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-368167     Document Type: Article

References (31)

1. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005; 23(22):5052-5060. (Pubitemid 46224012)
2. Hamlin PA. Treatment of aggresive non-Hodgkin's and Hodgkin's Lymphoma in older patients. Am Soc Clin Oncol Educ Book. 2007;295- 297.
3. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16(1):124-131. (Pubitemid 40124489)
4. Halbsguth TV, Boll B, Borchmann P, Diehl V. The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep. 2011;6(3): 164-171.
5. Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88(4): 438-444. (Pubitemid 36547130)
6. Mir R, Anderson J, Strauchen J, et al. Hodgkin disease in patients 60 years of age or older: histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer. 1993;71(5):1857-1866. (Pubitemid 23067406)
7. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol. 2002;20(4):1087-1093. (Pubitemid 34141854)
8. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol. 2009;71(3):222-232.
9. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008;22(12):1369-1379.
10. Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR. Hodgkin's disease in the elderly: a population-based study. Br J Haematol. 2002; 119(2):432-440. (Pubitemid 35365495)
11. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
12. Levis A, Merli F, Tamiazzo S, et al. ABVD versus VEPEMB in elderly Hodgkin's lymphoma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:2322.
13. Boll B, Görgen H, Fuchs M, von Tresckow B, Engert A, Borchmann P. Feasibility and efficacy of ABVD in elderly Hodgkin lymphoma patients: analysis of two randomized prospective multi-center trials of the German Hodgkin Study Group (HD10 and HD11) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:418.
14. Proctor SJ, Wilkinson J, Culligan D, et al. Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin lymphoma patients over 60 YS evaluated as part of the SHIELD (Hodgkin Elderly) study. Ann Oncol. 2011;22(suppl 4):117-118.
15. Evens AM, Hong F, Gordon LI, et al. Efficacy and tolerability of ABVD and Stanford V for Elderly Advanced-Stage Hodgkin-Lymphoma (HL): analysis from the Phase III Randomized US Intergroup Trial E2496. Ann Oncol. 2011;22(suppl 4): 118.
16. Enblad G, Glimelius B, Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol. 1991;2(4):297-302.
17. Enblad G, Gustavsson A, Sundstrom C, Glimelius B. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Acta Oncol. 2002;41(7):659-667. (Pubitemid 36106211)
18. Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12):2026-2032.
19. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18(13):2615-2619. (Pubitemid 30432529)
20. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colonystimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12(11):2471-2508.
21. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
22. Engert A, Kobe C, Markowa J, et al. Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: final report of the GHSG HD15 Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:764.
23. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010; 363(7):640-652.
24. Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117(20):5314-5320.
25. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients: results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15(1):123-128. (Pubitemid 38139613)
26. Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica. 1996;81(5):450-456.
27. Macpherson N, Klasa RJ, Gascoyne R, O'Reilly SE, Voss N, Connors JM. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma. 2002;43(7):1395-1402. (Pubitemid 34705023)
28. Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007;48(3):570-576. (Pubitemid 46487767)
29. Klimm B, Diehl V, Engert A. Hodgkin's lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park). 2007;21(8):982-990. (Pubitemid 47106312)
30. Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22(12):2424-2429. (Pubitemid 41115400)
31. Kurtz JE, Heitz D, Kurtz-Illig V, Dufour P. Geriatric oncology: how far have we gone and what are the next steps? Oncology. 2009;77(3):147-156.